Analysts Anticipate Hologic, Inc. (HOLX) Will Post Earnings of $0.49 Per Share
Analysts expect Hologic, Inc. (NASDAQ:HOLX) to post $0.49 earnings per share (EPS) for the current quarter, Zacks reports. Seven analysts have issued estimates for Hologic’s earnings. The lowest EPS estimate is $0.48 and the highest is $0.49. Hologic posted earnings per share of $0.52 during the same quarter last year, which suggests a negative year over year growth rate of 5.8%. The business is expected to report its next earnings results after the market closes on Wednesday, November 8th.
On average, analysts expect that Hologic will report full-year earnings of $2.01 per share for the current fiscal year, with EPS estimates ranging from $2.00 to $2.01. For the next fiscal year, analysts forecast that the company will report earnings of $2.17 per share, with EPS estimates ranging from $2.06 to $2.28. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Hologic.
Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. The business had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.51 EPS.
A number of research analysts have commented on HOLX shares. Deutsche Bank AG decreased their target price on shares of Hologic from $51.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) lowered shares of Hologic from a “conviction-buy” rating to a “buy” rating and cut their price target for the stock from $48.00 to $47.00 in a research note on Thursday, August 3rd. Needham & Company LLC reiterated a “buy” rating on shares of Hologic in a research note on Tuesday, August 1st. BidaskClub lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $51.00 price target on shares of Hologic in a research note on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $48.38.
In related news, Director Elaine Ullian sold 6,902 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total transaction of $276,908.24. Following the sale, the director now directly owns 23,810 shares in the company, valued at $955,257.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lawrence M. Levy sold 7,139 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $39.04, for a total transaction of $278,706.56. The disclosure for this sale can be found here. Insiders have sold 18,745 shares of company stock worth $768,189 over the last 90 days. Insiders own 0.79% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the stock. Stratos Wealth Partners LTD. increased its stake in shares of Hologic by 0.6% during the second quarter. Stratos Wealth Partners LTD. now owns 4,954 shares of the medical equipment provider’s stock worth $225,000 after buying an additional 30 shares during the period. Cleararc Capital Inc. increased its stake in shares of Hologic by 1.1% during the first quarter. Cleararc Capital Inc. now owns 6,843 shares of the medical equipment provider’s stock worth $291,000 after buying an additional 77 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of Hologic by 0.4% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 20,803 shares of the medical equipment provider’s stock worth $944,000 after buying an additional 85 shares during the period. Symphony Asset Management LLC increased its stake in shares of Hologic by 0.4% during the second quarter. Symphony Asset Management LLC now owns 28,005 shares of the medical equipment provider’s stock worth $1,271,000 after buying an additional 108 shares during the period. Finally, Advantus Capital Management Inc increased its stake in shares of Hologic by 0.4% during the first quarter. Advantus Capital Management Inc now owns 27,936 shares of the medical equipment provider’s stock worth $1,189,000 after buying an additional 116 shares during the period. Hedge funds and other institutional investors own 96.38% of the company’s stock.
Hologic (NASDAQ:HOLX) traded down 0.26% on Friday, reaching $37.69. 3,022,643 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $37.78 and a 200-day moving average of $42.13. Hologic has a one year low of $35.15 and a one year high of $46.80. The stock has a market cap of $10.57 billion, a price-to-earnings ratio of 14.04 and a beta of 0.91.
ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Hologic, Inc. (HOLX) Will Post Earnings of $0.49 Per Share” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/06/analysts-anticipate-hologic-inc-holx-will-post-earnings-of-0-49-per-share.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.